Biotech Growth to Slow Down in the US

239 views

Published on

Recombinant proteins, which currently account for around 60% of the total US biopharmaceutical sales, are expected to be the worst hit during the forecast period.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
239
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Biotech Growth to Slow Down in the US

  1. 1. Biotech Growth to Slow Down in the USRecombinant proteins, which currently account for around 60% of the total US biopharmaceuticalsales, are expected to be the worst hit during the forecast period.A new report from IMARC Group expects the biopharmaceutical market in the US to grow at a CAGRof around 5% during 2012-2017. This is significantly lower than the average 8-9% growth rateobserved in this market in the last five years.According to an analyst at IMARC Group, “the rise of biosimilars in the US is expected to have amajor impact on market growth. Recombinant proteins, which currently account for around 60% of thetotal US biopharmaceutical sales, are expected to be the worst hit during the forecast period. During2012-2017, we expect nine biological brands in this segment to face biosimilar competition.Recombinant proteins are expected to witness a CAGR growth of less than 3% during this period.The growth of monoclonal antibodies, on the other hand, is expected to be significantly faster thanrecombinant proteins during the forecast period. The key factors driving the monoclonal antibodieswill be a rich pipeline and approval of additional indications for currently marketed drugs. Althoughsome monoclonal antibodies such as Rituxan and Humira may face biosimilar competition, we expectsignificantly lower biosimilar threat for monoclonal antibodies during the forecast period compared torecombinant proteins.IMARC’s new report “Global Biopharmaceutical Market Report & Forecast (2012-2017)” gives adeep insight into the global biopharmaceutical market. The research study serves as an analytical aswell as a statistical tool to understand the strengths, weaknesses, opportunities, threats, markettrends, geographical structure, therapeutic structure, competitive structure and the outlook of theglobal biopharmaceutical market till 2017. This report will serve as an excellent guide for investors,researchers, consultants, marketing strategists, and all those who are planning to foray into the globalbiopharmaceutical market in any form.What We Have Achieved in this Report?Deep Qualitative Understanding of Various Factors Driving and Restraining the GlobalBiopharmaceutical MarketKey Aspects Analyzed: Driving Factors Restraining Factors Market Opportunities ThreatsComprehensive Situation Analysis of the Global Biopharmaceutical Market and its Dynamics
  2. 2. Regions/Countries Covered:North America: United States and CanadaLatin America: Mexico, Brazil and ArgentinaEurope: Germany, France, Italy, Spain, United Kingdom, Russia and TurkeyAsia Pacific: Japan, China, Australia, South Korea, India and IndonesiaClasses Covered for Each Country: Erythropoietins, Insulin, Interferons, Growth Hormones,Immunoglobulins, Colony Stimulating Factors, Recombinant Blood Factors, Recombinant Enzymes,Growth Factors, Interleukins, Monoclonal Antibodies and Purified ProteinsFocus of the Analysis for Each Country: Total Market Performance (2005 - 2011) Performance of Various Classes (2005 - 2011) Performance of Top Players (2005 - 2011) Market Forecast (2012 - 2017)Key Questions Answered in this Report: What are the key advantages/ disadvantages of biopharmaceuticals over small molecule drugs in terms of efficacy, safety, price, approval times, market growth, etc.? What are the key opportunities and threats faced by the biopharmaceutical industry? What has been the historical and current performance of the global biopharmaceutical market and how is it expected to perform in the coming years? Which are the world’s largest biopharmaceutical markets? Which are the world’s fastest growing biopharmaceutical markets? What is the structure and composition of various biopharmaceutical markets across the globe? Which are the world’s largest biopharmaceutical segments? Which are the world’s fastest growing biopharmaceutical segments? Who are the world’s largest biopharmaceutical companies and how have they performed in recent years?To buy the complete report or to get a free sample, please contact:IMARC Group AsiaEmail: apac@imarcgroup.comPhone: +91-120-415-5099IMARC Group North AmericaEmail: america@imarcgroup.com
  3. 3. Phone: +1-631-791-1145IMARC Group Europe, Middle East & AfricaEmail:ema@imarcgroup.comPhone: +44-702-409-7331To know more please visit: http://www.imarcgroup.com/global-biopharmaceutica-market-report-forecasts-2012-2017/http://www.imarcgroup.com/biosimilarfollow-on-biologics-market-report-forecast-a-focus-on-the-us-2011-2020/

×